September 14, 2017
Adults with poorly controlled type 2 diabetes and severe obesity saw sustained reductions in body weight and HbA1c after receiving an endoscopically implanted weight-loss device for 1 year along with lifestyle intervention, according to findings presented at the European Association for the Study of Diabetes Annual Meeting.
The EndoBarrier (GI Dynamics) is a thin plastic sleeve that lines the first 60 cm of the small intestine, causing food to be absorbed further down in the intestine, according to a description from the manufacturer. In a small study, Robert Ryder, MD, consultant diabetologist at City Hospital in Birmingham, United Kingdom, and colleagues analyzed data from 31 adults with type 2 diabetes and obesity aged 28 to 62 years who had the device implanted after October 2014 and removed after 1 year (mean age, 51 years; 58% men; 48% white; mean diabetes duration, 13.3 years). Within the cohort, 54.8% were on insulin therapy. All participants were also counseled on lifestyle management.